MSAB|cas:173436-66-3|西域试剂

MSAB,99.77%

产品编号：Bellancom-120697| CAS NO：173436-66-3| 分子式：C₁₅H₁₅NO₄S| 分子量：305.35

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-120697	￥790.00	杭州北京（现货）
Bellancom-120697	￥1265.00	杭州北京（现货）
Bellancom-120697	￥2404.00	杭州北京（现货）
Bellancom-120697	￥3847.00	杭州北京（现货）
Bellancom-120697	￥6154.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MSAB

产品介绍

MSAB 是 Wnt/β-catenin 信号传导的有效和选择性抑制剂。MSAB 与 β-catenin 结合，促进其降解，并特别下调 Wnt/β-catenin 靶基因。MSAB 对 Wnt 依赖性癌细胞显示出有效的抗肿瘤作用。

生物活性

MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells.

体外研究

MSAB (2-10 μM) selectively decreases cell viability of Wnt-dependent cells while showing little effect on Wnt-independent cells and normal human cells.
MSAB (0.01-10 μM; 20 h) inhibits T-cell factor (TCF) luciferase reporter activity in HCT116 cells.
MSAB (20 h) suppresses the Wnt3a-induced TOP-Luc activation and increases of active β-catenin levels in HEK293T cells.
MSAB (0.5-10 μM; 20 h) decreases mRNA and protein levels of endogenous Wnt target genes in HCT116 cells.
MSAB (5 μM; 16 h) induces degradation of β-catenin in a proteasome-dependent manner in HCT116 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MSAB (10-20 mg/kg; i.p. daily for 2 weeks) inhibits tumor growth of Wnt-dependent cancer cells in mouse xenograft model.
MSAB (10-20 mg/kg; i.p. twice daily for 2 weeks) inhibits tumor growth of MMTV-Wnt1 transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice (5-6 weeks) are injected HCT116, HT115, H23, or H460 cells
Dosage:	10, 20 mg/kg
Administration:	I.p. daily for 2 weeks
Result:	Reduced the size and weight of various types of Wnt-dependent HCT116, HT115, and H23 tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice (5-6 weeks) are injected HCT116, HT115, H23, or H460 cells
Dosage:	10, 20 mg/kg
Administration:	I.p. daily for 2 weeks
Result:	Reduced the size and weight of various types of Wnt-dependent HCT116, HT115, and H23 tumors.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (818.73 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2749 mL	16.3747 mL	32.7493 mL
5 mM	0.6550 mL	3.2749 mL	6.5499 mL
10 mM	0.3275 mL	1.6375 mL	3.2749 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.81 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.81 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.81 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.81 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。